In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1422500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Shila Kumari Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Sciences, Assam Downtown University, Guwahati, Assam, India. Hauptthemen laut MEDLINE: Staphylococcus aureus, Molecular Docking Simulation, Molecular Dynamics Simulation, Anti-Bacterial Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.
Abstract (Originalsprache)
Introduction
Staphylococcus aureus is a highly resistant pathogen. It has multiple virulence factors, which makes it one of the most pathogenic bacteria for humankind. The vast increase in antibiotic resistance in these bacteria is a warning of existing healthcare policies. Most of the available antibiotics are ineffective due to resistance; this situation requires the development of drugs that target specific proteins and are not susceptible to resistance.
Methods
In this study, we identified a compound that acts as an antagonist of ClfA and ClfB by inhibiting their binding to host cells.
Results
The shortlisted compound’s binding activity was tested by docking and molecular dynamics during its interaction with proteins. The identified compound has excellent binding energy with both ClfA (-10.11 kcal/mol) and ClfB (-11.11 kcal/mol).
Discussion
The molecular dynamics of the protein and compound were stable and promising for further in vitro and in vivo tests. The performance of our compound was tested and compared with that of the control molecule allantodapsone, which was reported in a previous study as a pan inhibitor of the clumping factor. An ADMET study of our selected compound revealed its reliable drug likeliness. This compound is an ideal candidate for in vitro studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Sciences, Assam Downtown University, Guwahati, Assam, India.
- Department of Research, Central India Institute of Medical Science, Nagpur, Maharasthra, India.
- College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Biochemistry, Andrew Taylor Still University of Health Science, Kirksville, MO, United States.
- College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Förderung
- King Saud University
Zitieren
APA
Singh, S. K., Bhattacharjee, M., Unni, B., Kashyap, R. S., Malik, A., Akhtar, S., & Fatima, S. (2024). In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1422500
Vancouver
Singh SK, Bhattacharjee M, Unni B, Kashyap RS, Malik A, Akhtar S, et al. In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1422500
BibTeX
@article{Singh2024,
author = {Singh, Shila Kumari and Bhattacharjee, Minakshi and Unni, Balagopalan and Kashyap, Rajpal Singh and Malik, Abdul and Akhtar, Suhail and Fatima, Sabiha},
title = {In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1422500}
}
EUVIMED